Insiders sold $437K, 0% under disclosed plans. Their starting stakes can't be measured from the filings because most of the sellers' shares vested during the period.
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| John Higgins Director | 5,562 | $72.51 | 6.7% | 77K | Sep 28, 2026 | Sep 30, 2026 |
"% of total stake" is the shares in this event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings don't reconcile, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| Robert Baumgartner Director | 5,559 | $72.55 | 8.9% | 57K | Sep 22, 2026 | Sep 24, 2026 |
"% of total stake" is the shares in this event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings don't reconcile, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.
Percentages cover 14 of 15 officers and directors. Left out: Amy Herr (most of their shares vested during the period, so a percentage would mislead). Disclosed company stock is not an insider's whole wealth.
Officers and directors, past 12 months. Each bar is the insider's vested stake at the start of the period (Oct 8, 2025). The gold part is what they sold.
Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
No. Kim Kelderman reported no open-market sales in the past 12 months.
Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 0% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 100% had no disclosed plan. A trading plan schedules sales in advance.
No. Officers and directors reported no purchases in the past 12 months.
| Who sold | Amount | % of holdings | Trading plan |
|---|---|---|---|
| Amy Herr Director | $437K 8.6K shares | iNo percentage: most of their shares vested during the period, so a percentage would mislead. | No plan disclosed |
Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.
| Insider | Held Oct 8, 2025 | Sold | Held Oct 8, 2026 | Still held | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
James HippeliIncludes unvested RSUs, amount not disclosed. CFO | 130K | 0 | 170K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for James Hippel+221Kshares vested or exercised 0gifted (net of own trusts) −180Kwithheld by the company for taxes 194K → 206Kunvested awards, start → end
Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| John Higgins Director | 65K | 0 | 77K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for John Higgins+16Kshares vested or exercised 0gifted (net of own trusts) −5.6Kwithheld by the company for taxes none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Kim Kelderman Chief Executive Officer, Director | 51K | 0 | 83K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Kim Kelderman+131Kshares vested or exercised 0gifted (net of own trusts) −99Kwithheld by the company for taxes 238K → 351Kunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Robert Baumgartner Director | 45K | 0 | 57K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Robert Baumgartner+16Kshares vested or exercised 0gifted (net of own trusts) −5.6Kwithheld by the company for taxes none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Roeland Nusse Director | 45K | 0 | 45K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Roeland Nusse0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
William GeistiIncludes unvested RSUs, amount not disclosed. President, Protein Sciences | 15K | 0 | 25K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for William Geist+16Kshares vested or exercised 0gifted (net of own trusts) −6.5Kwithheld by the company for taxes 104K → 118Kunvested awards, start → end
Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alpna Seth Director | 14K | 0 | 15K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Alpna Seth0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Joseph Keegan Director | 14K | 0 | 15K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Joseph Keegan0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rupert Vessey Director | 9.3K | 0 | 11K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Rupert Vessey0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Julie Bushman Director | 7.1K | 0 | 8.8K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Julie Bushman0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Steven CrouseiStarted reporting during the period; starting holdings are from the Form 3. President - Diag & Spatial Bi | 5.9K | 0 | 10K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Steven Crouse+6.8Kshares vested or exercised 0gifted (net of own trusts) −2.5Kwithheld by the company for taxes 15K → 34Kunvested awards, start → end
Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Matthew McManus President - Diag & Spatial Bio | 4.7K | 0 | 7.7K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Matthew McManus+4.6Kshares vested or exercised 0gifted (net of own trusts) −1.7Kwithheld by the company for taxes 65K → 60Kunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shane Bohnen SVP - General Counsel | 4.4K | 0 | 10K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Shane Bohnen+15Kshares vested or exercised 0gifted (net of own trusts) −9.5Kwithheld by the company for taxes 41K → 60Kunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Amy Herr Director | 3.2K | −8.6K | 3.3K | not meaningful | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Amy Herr+7.3Kshares vested or exercised 0gifted (net of own trusts) −229withheld by the company for taxes 1.5K → 2.2Kunvested awards, start → end
Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Judith Klimovsky Director | 2.1K | 0 | 3.8K | no sales | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Judith Klimovsky0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($48.28 − strike price), using the most recent insider trade price on Form 4 (May 8, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 of 15 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (15 exactly, 0 with a minor or footnoted difference). Percentages cover 14 of 15 officers and directors. Left out: Amy Herr (most of their shares vested during the period, so a percentage would mislead). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.
Officer and director open-market sales: $437K across 8,612 shares. Plan status and stated purpose are separate questions, and a sale can have both.
Sales with no 10b5-1 plan and no tax reference in the filing. $437K of it is Amy Herr. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Amy Herr, May 8, 2026
310,930 shares ($19.6M) were withheld by the company for taxes, which isn't a market sale.
| Seller | Shares sold | Proceeds | Under a disclosed plan | Share of total | Sales dates |
|---|---|---|---|---|---|
| Amy Herr Director | 8.6K | $437K | 0% | 100% | Feb 17, 2026 to May 8, 2026 |
| Month | Sale proceeds | Disclosed plan | To cover taxes | No plan disclosed |
|---|---|---|---|---|
| Oct 2025 | $0 | $0 | $0 | $0 |
| Nov 2025 | $0 | $0 | $0 | $0 |
| Dec 2025 | $0 | $0 | $0 | $0 |
| Jan 2026 | $0 | $0 | $0 | $0 |
| Feb 2026 | $117K | $0 | $0 | $117K |
| Mar 2026 | $0 | $0 | $0 | $0 |
| Apr 2026 | $0 | $0 | $0 | $0 |
| May 2026 | $320K | $0 | $0 | $320K |
| Jun 2026 | $0 | $0 | $0 | $0 |
| Jul 2026 | $0 | $0 | $0 | $0 |
| Aug 2026 | $0 | $0 | $0 | $0 |
| Sep 2026 | $0 | $0 | $0 | $0 |
| Oct 2026 | $0 | $0 | $0 | $0 |
Less than usual: less than one-twentieth of the 5-year average. 1 insider sold; the average is 5 a year.
| 12 months ending | Shares sold | Insiders who sold | Proceeds |
|---|---|---|---|
| Oct 8, 2026 Latest 12 months | 8.6K | 1 | $437K |
| Oct 8, 2025 1 year earlier | 51K | 4 | $3.1M |
| Oct 8, 2024 2 years earlier | 30K | 3 | $2.3M |
| Oct 9, 2023 3 years earlier | 98K | 3 | $8.5M |
| Oct 9, 2022 4 years earlier | 187K | 5 | $22.5M |
| Oct 9, 2021 5 years earlier | 1.01M | 10 | $98.8M |
Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.
Every officer and director reconciles for this period.
Inferred rename: "stock bonus plan for spouse" is treated as the same holder as "IRA for spouse", because the old name was never reported again and the new one opened with the same balance (150,392 shares). Old name, new name
External context: we only cite outside events when a documented connection exists. None is shown for this period.
All 679 Forms 3, 4 and 5 filed for BIO-TECHNE Corp (SEC CIK 842023) from May 14, 2003 to Sep 30, 2026, retrieved from SEC EDGAR on Oct 8, 2026. Prices are the ones reported in each filing, often weighted averages. 2 filings were left out because BIO-TECHNE Corp filed them as an owner of another company's stock.
Probable 4-for-1 stock split on or before Dec 7, 2022 (first filing that shows post-split balances). Splits aren't reported as transactions; 17 holding lines changed by exactly this ratio, so earlier share counts are restated.
Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.
Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".